Nyrada, Inc. · ASX:NYR
Nyrada — Shareholder Meeting (November 2024)
13 slides from Nyrada's shareholder meeting presentation, Nov 12, 2024
Slide 1: AGM Presentation
For personal use only AGM Presentation James Bonnar Chief Executive Officer 12 November 2024 | Sydney Australia ASX:NYR Improving Lives, Offering Hope Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 3: About Nyrada
About Nyrada › Drug discovery and development company specialising in rational design of novel small molecule therapeutics. For personal use only › Nyrada’s lead drug candidate NYR-BI03: › demonstrated strong preclinical efficacy protecting the brain from secondary injury following stroke. › demonst
Slide 4: Vision and Strategy
Vision and Strategy For personal use only Our Vision: • to become a high-growth pharmaceutical company specialising in the discovery and development of novel treatments Our Strategy: • to develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptima
Slide 5: Nyrada's Lead Drug Candidate NYR-BI03
Nyrada’s Lead Drug Candidate NYR-BI03 For personal use only First-in-Class with Novel Significant Unmet Clinical Need Mechanism of Action and Market Opportunity › NYR-BI03 is a first-in-class therapy. › Targeting multiple indications. › Novel mechanism of action. › Stroke, TBI and ischemia- Reperfus
Slide 6: One Drug, Two Applications, Three Markets
One Two Three Drug Applications Markets For personal use only STROKE NYR-BI03 Neuroprotection Commencing ~US$52.2 billion by 20322 Phase Ia clinical trial in late CY2024 TRAUMATIC BRAIN INJURY ~US$5.5 billion by 20344 Cardioprotection MYOCARDIAL INFARCTION ~US$3.7 billion by 20325 6
Slide 7: Neuroprotection – Stroke and TBI
Neuroprotection – Stroke and TBI Serial reconstruction from MRI For personal use only Secondary Disability Primary Injury Injury Level 30 mins BECAME STAYED THE DIED WORSE SAME IMPROVED 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyrada drug NYR-BI03 • Impro
Slide 8: Cardioprotection
Cardioprotection Key Preclinical Results: NYR-BI03 showed strong For personal use only efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional shortenin
Slide 9: Indicative Phase I Study Design
Indicative Phase I Study Design For personal use only OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 DESIGN • Randomised, double-blind PARTICIPANTS placebo –controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8 participants each • 18
Slide 10: Financial Overview and Outlook
Financial Overview and Outlook For personal use only FY2024 Highlights and FY2025 Outlook Operating Results Summary › Resources FY2024 FY2023 (AU$) (AU$) › Cash balance of AU$2.98 million at 30 September 2024 R&D Costs 2,030,502 6,411,264 › Expected R&D rebate of AU$1.38 Corporate and admin million
Slide 11: Conclusion
Conclusion › Summary For personal use only › Pioneering transient receptor potential canonical (TRPC) channel blocking therapies. › First-in-class neuroprotection and cardioprotection therapy with novel mode of action. › One drug asset targeting two significant therapeutic areas and three large mark
Slide 12: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- For personal use only accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20i s%20high%20blood%20pressure 2 – Databridge Market Research - https://www.databridgemar
Slide 13: For personal use only
For personal use only @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 13